

Synthesis of some oxazolo[4,5-*d*]pyrimidine derivatives and evaluation of their antiviral activity and cytotoxicity

Yevheniia Velihina,^a Stepan Pil'ov,^a Oleksandr Kobzar,^a Olena Zaliavska,^b Mark N. Prichard,^{c**} Scott H. James,^c Kathy Keith,^c Caroll Hartline,^c Victor Zhirnov,^a Andriy Vovk,^a and Volodymyr Brovarets*^a

^aV.P. Kukhar Institute of Bioorganic Chemistry and Petrochemistry of the NAS of Ukraine, 1, Murmanska St, Kyiv 02094, Ukraine

^bDepartment of Internal Medicine, Clinical Pharmacology and Occupational Diseases, Bukovinian State Medical University, 2, Sq. Teatralna, Chernivtsi 58002, Ukraine

^cDepartment of Pediatrics, Division of Pediatric Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama 35233, USA

Email: brovarets@bpci.kiev.ua

Dedicated to Prof. Girolamo Cirrincione in recognition of his outstanding contributions to the fields of organic and medicinal chemistry at the occasion of on the occasion of his retirement


Received mm-dd-yyyy

Accepted Manuscript mm-dd-yyyy

Published on line mm-dd-yyyy

Abstract

New oxazolo[4,5-*d*]pyrimidine derivatives were synthesized and their some physicochemical and ADMET properties were analyzed by *in silico* prediction. Antiviral activity against DNA viruses (human cytomegalovirus, varicella-zoster virus, herpes simplex virus and BK virus) and cytotoxicity, including control experiments, were evaluated *in vitro*. Some of the compounds synthesized were characterized by low toxicity; however, they did not exhibit favorable antiviral effects.



Antiviral evaluation
Cell toxicity
Pharmacokinetic properties

Keywords: Oxazolo[4,5-*d*]pyrimidine derivatives, synthesis, antiviral activity, cytotoxicity

Introduction


Oxazole and pyrimidine scaffolds, as well as their fused heterocycles, are well-known structures utilized in the design of bioactive molecules in drug discovery. A significant number of studies have been carried out on the biological properties of oxazolo[5,4-*d*]pyrimidines, uncovering their activities as receptor modulators and enzyme inhibitors.¹ However, it seems that oxazolo[4,5-*d*]pyrimidines have only been synthesized, and that there is little information in the literature concerning their bioactivity.² Among these bioactivity reports, inhibition of fatty acid amide hydrolase and monoglyceride lipase³ by these compounds have been described. Some of oxazolo[4,5-*d*]pyrimidine derivatives were also shown to exhibit anticancer activity.⁴⁻⁶ Since oxazole- and pyrimidine-based heterocycles, including oxazolo[5,4-*d*]pyrimidines, have demonstrated antiviral effects,⁷⁻⁹ the synthesis of new compounds that contain oxazolo[4,5-*d*]pyrimidine fragment was of interest to us and therefore we decided to synthesize them and to evaluate their antiviral activity and toxicity.

In this paper, new oxazolo[4,5-*d*]pyrimidine derivatives were synthesized, characterized *in silico* on drug-like properties and tested *in vitro* for cell cytotoxicity and efficacy against some viral opportunistic infections.

Results and Discussion

Synthesis of target oxazolo[4,5-*d*]pyrimidines


The synthesis of oxazolo[4,5-*d*]pyrimidines **1-9** is depicted in Scheme 1 and was carried out by a route described previously.⁴⁻⁶ Available oxazolones **I** were used as starting substrates. Oxazolo[4,5-*d*]pyrimidin-7(6*H*)-ones **III** were obtained through a simple sequence of the reactions **I** → **II** → **III** (scheme 1).¹⁰ The chlorination of these compounds (POCl₃ (excess), Me₂NPh, 105 – 110 °C) afforded 7-chlorosubstituted oxazolo[4,5-*d*]pyrimidines **IV**.^{4-6,10} Treatment of compounds **IV** with the primary or secondary amines, in the presence of triethylamine in dioxane, resulted in high yields of the corresponding 7-aminesubstituted oxazolo[4,5-*d*]pyrimidines **1-9**. The synthesis of oxazolo[4,5-*d*]pyrimidines **V** was accomplished in analogy to previously reported compounds.⁴⁻⁶



Scheme 1. Synthesis of oxazolo[4,5-*d*]pyrimidines **1-15**. Reagents and conditions: (a) amidine hydrochlorides, Et₃N, THF, r.t., 48h; (b) Py, reflux, 10h; (c) POCl₃, Me₂NPh, 105 – 110 °C, 3h; (d) corresponding amine, dioxane, reflux, 6h.

The treatment of derivatives **V** with alkyl- or arylsulfonyl chlorides, in the presence of triethylamine and on heating in dioxane, led to new oxazolo[4,5-*d*]pyrimidines **10-15** (scheme 2). The composition and structure of compounds **1-15** were confirmed by elemental analysis, ¹H and ¹³C NMR spectra and LC-MS spectrometry.

The synthesized compounds **1-15** (figure 1) are represented by 5-(4-methylphenyl)-2-phenyl-7-substituted oxazolo[4,5-*d*]pyrimidine derivatives **1-9**, 2-(4-methylphenyl)-5-phenyl-7-substituted oxazolo[4,5-*d*]pyrimidine derivatives **10-12**, **14**, **15**, and 2,5-diphenyl-7-substituted oxazolo[4,5-*d*]pyrimidine **13**. The physicochemical properties of the molecules were modulated by the nature of the substituent at position 7.



Scheme 2. Synthesis of oxazolo[4,5-*d*]pyrimidines **10-15**. Reagents and conditions: (e) piperazine or 1,4-diazepane, dioxane, reflux, 6h; (f) corresponding RSO₂Cl, Et₃N, dioxane, 105 – 110 °C, 6h.




Figure 1. Synthesized oxazolo[4,5-*d*]pyrimidine derivatives **1-15**.

Investigation of molecular properties and drug-like parameters

Drug-like parameters (Table 1), as calculated by Molinspiration software (<http://www.molinspiration.com>), indicated that only four of the 15 synthesized compounds are in compliance with Lipinski rule of five.¹¹ Two-thirds of the derivatives have molecular weights lower than 500 Da. According to the predictive software, only compounds **5**, **6**, **10**, and **13** are expected to have logP values lower than 5, and the other oxazolo[4,5-*d*]pyrimidine derivatives are more lipophilic. All of the compounds were predicted to have H-bond accepting abilities in the range of 5-8, and less than half of them can be characterized by one H-bond donating group. The topological polar surface area prediction values (from 64 to 94) were found to be in the acceptable range. Pharmacokinetic properties (Table 1 and Table S1) predicted by the pkCSM online server¹² suggested that all the oxazolo[4,5-*d*]pyrimidine derivatives could potentially have good human intestinal absorption, and compound **1** can also have a good possibility in terms of blood-brain barrier permeability.

Table 1. Some physicochemical parameters and pharmacokinetic properties of oxazolo[4,5-*d*]pyrimidines **1-15**

Compd	Molecular weight	miLogP ^a	nOHNH ^b	nON ^c	nrotb ^d	TPSA ^e , Å ²	Intestinal absorption (human), %	BBB permeability, logBB
1	410.45	6.15	1	5	5	63.84	93.366	0.701
2	436.51	6.45	1	6	7	73.08	91.915	-0.393
3	526.04	6.72	1	7	7	76.31	92.473	-0.370
4	497.62	5.94	1	7	7	76.31	92.322	-0.405
5	413.48	4.34	2	7	4	98.15	97.038	-0.862
6	386.45	4.59	1	6	3	75.28	96.449	-0.640
7	424.50	5.28	0	6	3	72.12	95.794	-0.697
8	476.58	5.24	0	7	6	71.18	97.391	-0.861
9	490.61	5.51	0	7	6	71.18	96.989	-0.882
10	449.54	4.10	0	8	4	92.43	95.375	-1.209
11	511.61	5.63	0	8	5	92.43	100	-1.245
12	525.63	6.08	0	8	5	92.43	100	-1.255
13	435.51	3.65	0	8	4	92.43	95.809	-1.231
14	525.63	5.90	0	8	5	92.43	100	-1.240
15	539.66	6.35	0	8	5	92.43	100	-1.250

^amiLogP – LogP prediction method developed at Molinspiration. ^bnOHNH – Number of OH and NH groups as H-bond donors. ^cnON – Number of O and N atoms as H-bond acceptors. ^dnrotb – Number of rotatable bonds. ^eTPSA – Topological polar surface area.

Antiviral and Cytotoxicity Assays

Activity against human cytomegalovirus (HCMV), varicella-zoster virus (VZV), herpes simplex virus (HSV-1) and BK virus (BKV) was assessed via *in vitro* antiviral assays. The data obtained in the study, along with positive controls for each virus, are given in Table 2. Only compound **3** showed activity against BKV with EC₅₀ of 3.51 μM and CC₅₀ of 23.53 μM (selectivity index SI₅₀ is 7), and none of the other compounds demonstrated favorable antiviral activity. At the same time, CC₅₀ values indicated a high degree of cytotoxicity of many of the

tested compounds. It should also be noted, that *in silico* ADMET profile showed that the compounds could potentially inhibit hERG II and exhibit hepatotoxicity (Table S1).

Table 2. *In vitro* antiviral activity and cell cytotoxicity of oxazolo[4,5-*d*]pyrimidine derivatives **1-15** in primary assay

Compd	HCMV ^a		VZV ^b		BKV ^c		HSV-1 ^d	
	EC ₅₀	CC ₅₀	EC ₅₀	CC ₅₀	EC ₅₀	CC ₅₀	EC ₅₀	CC ₅₀
1	>6.00	13.79	>1.20	3.76	ND ^e	ND	>1.20	4.04
2	>1.20	4.83	>6.00	16.88	>6.00	17.19	>1.20	4.80
3	>6.00	20.63	>30.00	37.54	3.51	23.53	>6.00	19.62
4	>1.20	5.82	>6.00	21.47	15.12	37.24	>6.00	17.53
5	>150.00	>150.00	>150.00	>150.00	ND	ND	>150.00	>150.00
6	>150.00	>150.00	62.07	>150.00	ND	ND	>150.00	>150.00
7	>30.00	91.42	>30.00	87.35	ND	ND	>30.00	77.65
8	>150.00	>150.00	>150.00	>150.00	>150.00	>150.00	>30.00	110.00
9	>1.20	3.14	>1.20	3.64	>1.20	5.32	>1.20	2.96
10	114.11	>150.00	139.62	>150.00	>150.00	>150.00	>150.00	>150.00
11	>30.00	88.41	>30.00	73.83	>150.00	>150.00	>30.00	78.34
12	>30.00	96.24	>6.00	16.94	>30.00	86.07	>6.00	15.92
13	>150.00	>150.00	81.07	>150.00	119.82	>150.00	>150.00	>150.00
14	>30.00	105.32	>30.00	100.07	>30.00	93.31	>30.00	117.00
15	>1.20	3.05	>1.20	3.16	>1.20	5.27	>1.20	3.32

Positive controls: ^aGanciclovir: 1.10, 0.68, 0.94 (EC₅₀); >150.00 (CC₅₀); ^bAcyclovir: 3.28, 2.25 (EC₅₀); >150.00 (CC₅₀); ^cCidofovir: 0.42 (EC₅₀); >100.00 (CC₅₀); ^dAcyclovir: 0.72, 0.78 (EC₅₀); >150.00 (CC₅₀).
^eND – not determined.

Giving the *in vitro* cytotoxicity results, we analyzed the possible link between the toxicity of the tested compounds and their lipophilicity. Cytotoxic compounds **1-4**, **9**, and **15** have calculated logP values from 5.51 to 6.72, while the compounds with low toxicity (CC₅₀ >150 μM), **5**, **6**, **8**, **10**, **13**, are characterized by logP values from 3.65 to 5.24. This indicates that high lipophilicity of the oxazolo[4,5-*d*]pyrimidine derivatives may cause their high toxicity, probably due to higher permeability through the membrane and binding to intracellular targets of both infected and non-infected cells.

Conclusions

New oxazolo[4,5-*d*]pyrimidine derivatives were synthesized and their antiviral activities against four DNA viruses were evaluated *in vitro*. Some of physicochemical and pharmacological properties of the compounds were predicted *in silico*. Biologically relevant antiviral assays demonstrated a lack of antiviral effects of the compounds, with cytotoxicity being a major limitation in many of them. This could be due to the high predicted logP values for the compounds and is consistent with predicted good human intestinal absorption.

Therefore, the main task of further functionalization of the oxazolo[4,5-*d*]pyrimidine framework is to reduce their toxicity and increase the selectivity.

Experimental Section

General. All chemicals and solvents for the synthetic work were acquired from commercial sources and used without further purification. Reaction monitoring by thin layer chromatography was performed on pre-coated alumina plates SiO₂ 60 F₂₅₄ from Merck. Melting points were determined on a Fisher-Johns apparatus. ¹H and ¹³C NMR spectra were recorded on Bruker Avance DRX 500 or Varian Mercury 400 spectrometers in DMSO-*d*₆ or CDCl₃ taking its residual protons signal as a standard. Data are reported as follows: chemical shift, multiplicity (*s* = singlet, *d* = doublet, *t* = triplet, *q* = quartet, *m* = multiplet), integration, and assignment. Broad signals are indicated as br. Coupling constants (*J*) are given in Hertz [Hz]. LC-MS identification was conducted on an Agilent 1200 Series system equipped with a diode array and a G6130A mass-spectrometer (atmospheric pressure electrospray ionization). Combustion elemental analysis was performed by hand in the V.P. Kukhar Institute of Bioorganic Chemistry and Petrochemistry analytical laboratory. The Carbon and Hydrogen contents were determined using the Pregl gravimetric method, Nitrogen – using the Duma's gasometrical micromethod, Sulfur – by the Scheininger titrimetric method, Chlorine – by the mercurimetric method. Oxazolo[4,5-*d*]pyrimidines **IV**, **V** were synthesized according to previously described methods.^{4,5}

General procedure for the synthesis of 7-aminesubstituted oxazolo[4,5-*d*]pyrimidines 1-9. A mixture of compound **IV** (2 mmol), one of amines (2 mmol) and Et₃N (2 mmol) in dioxane (10 mL) was refluxed for 6 h. After removal of the solvent, the residue was triturated with water, filtered off, dried and recrystallized from mixture of acetonitrile and dimethylformamide (5:1) obtaining white solids that are described below.

N-(4-Fluorobenzyl)-5-(4-methylphenyl)-2-phenyl-oxazolo[4,5-*d*]pyrimidin-7-amine (1). Yield: 80%. mp 190 – 192 °C. ¹H-NMR (400 MHz, DMSO-*d*₆): δ 8.76 (*s*, 1H, H-N), 8.26 (*d*, *J* 8.0 Hz, 2H, ArH), 8.21 (*d*, *J* 6.8 Hz, 2H, ArH), 7.71 – 7.63 (*m*, 3H, ArH), 7.54 – 7.49 (*m*, 2H, ArH), 7.28 (*d*, *J* 8.0 Hz, 2H, ArH), 7.17 (*t*, *J* 8.9 Hz, 2H, ArH), 4.84 (*d*, *J* 6.0 Hz, 2H, CH₂), 2.36 (*s*, 3H, Me). ¹³C-NMR (101 MHz, DMSO-*d*₆): δ 164.3, 162.5, 160.1, 159.9, 139.6, 136.5, 135.8, 135.3, 132.7, 129.8, 129.4, 129.0, 127.8, 127.5, 126.0, 115.2, 115.0, 42.8, 21.0. MS: 411.0 ([*M* + H]⁺, C₂₅H₂₀FN₄O⁺, calc. 411.2). Anal. calc. for C₂₅H₁₉FN₄O (410.15): C 73.16, H 4.67, N 13.65, found: C 73.13, H 4.65, N 13.58.

N-(4-Methoxyphenethyl)-5-(4-methylphenyl)-2-phenyl-oxazolo[4,5-*d*]pyrimidin-7-amine (2). Yield: 82%. mp 151 – 153 °C. ¹H-NMR (400 MHz, DMSO-*d*₆): δ 8.29 (br *d*, *J* 7.9 Hz, 3H, ArH, NH), 8.23 – 8.20 (*m*, 2H, ArH), 7.72 – 7.65 (*m*, 3H, ArH), 7.31 (*d*, *J* 7.9 Hz, 2H, ArH), 7.26 – 7.23 (*m*, 2H, ArH), 6.87 (*d*, *J* 8.0 Hz, 2H, ArH), 3.84 – 3.80 (*m*, 2H, CH₂), 3.71 (*s*, 3H, MeO), 2.96 (*t*, *J* 7.5 Hz, 2H, CH₂), 2.38 (*s*, 3H, Me). ¹³C-NMR (126 MHz, DMSO-*d*₆): δ 131.6, 129.0, 128.2, 127.5, 127.2, 125.4, 113.3, 54.4, 20.6. MS: 437.0 ([*M* + H]⁺, C₂₇H₂₅FN₄O₂⁺, calc. 437.2). Anal. calc. for C₂₇H₂₄N₄O₂ (436.19): C 74.29, H 5.54, N 12.84, found: C 74.30, H 5.50, N 12.78.

N-(2-(4-Chlorophenyl)-2-morpholinoethyl)-5-(4-methoxyphenethyl)-2-phenyl-oxazolo[4,5-*d*]pyrimidin-7-amine (3). Yield: 78%. mp 225 – 227 °C. ¹H-NMR (400 MHz, DMSO-*d*₆): δ 8.29 – 8.10 (*m*, 5H, ArH), 7.71 – 7.65 (*m*, 3H, ArH), 7.37 (br *s*, 4H, ArH), 7.29 (*d*, *J* 7.8 Hz, 2H, ArH), 4.26 – 4.23 (*m*, 1H, CH), 3.92 – 3.84 (*m*, 2H, CH₂), 3.56 – 3.54 (*m*, 4H, CH₂), 2.45 (br *s*, 4H, CH₂), 2.37 (*s*, 3H, Me). ¹³C-NMR (126 MHz, CDCl₃): δ 161.4, 147.9, 140.4, 135.4, 132.6, 130.2, 129.2, 128.4, 128.2, 126.5, 120.0, 50.7, 21.6. Anal. calc. for C₃₀H₂₈N₄O₂ (525.19): C 68.50, H 5.37, Cl 6.74, N 13.31, found: C 68.48, H 5.40, Cl 6.68, N 13.25.

N-(2-Morpholino-2-(thiophen-2-yl)ethyl)-5-(4-methoxyphenethyl)-2-phenyl-oxazolo[4,5-d]pyrimidin-7-amine (4). Yield: 75%. mp 226 – 228 °C. ¹H-NMR (400 MHz, DMSO-*d*₆): δ 8.28 – 8.26 (*m*, 3H, ArH, NH), 8.20 (*br d*, *J* 7.1 Hz, 2H, ArH), 7.70 – 7.63 (*m*, 3H, ArH), 7.49 – 7.47 (*m*, 1H, HetH), 7.29 (*d*, *J* 7.9 Hz, 2H, ArH), 7.10 (*d*, *J* 3.5 Hz, 1H, HetH), 7.06 – 7.04 (*m*, 1H, HetH), 4.33 (*t*, *J* 6.9 Hz, 1H, CH), 4.22 – 4.16 (*m*, 1H, CH), 4.05 – 4.03 (*m*, 1H, CH), 3.97 – 3.94 (*m*, 1H, CH), 3.83 (*t*, *J* 4.7 Hz, 1H, CH), 3.55 (*br s*, 2H, CH₂), 2.58 (*br s*, 2H, CH₂), 2.37 (*s*, 3H, Me). ¹³C-NMR (126 MHz, DMSO-*d*₆): δ 159.9, 154.8, 139.6, 132.7, 129.4, 129.0, 127.8, 127.7, 127.6, 126.7, 125.2, 66.5, 66.0, 49.5, 21.0. Anal. calc. for C₂₈H₂₇N₅O₂S (497.19): C 67.58, H 5.47, N 14.07, S 6.44, found: C 67.60, H 5.51, N 14.10, S 6.48.

1-(5-(4-Methylphenyl)-2-phenyl-oxazolo[4,5-d]pyrimidin-7-yl)piperidine-4-carboxamide (5). Yield: 70%. mp 299 – 301 °C. ¹H-NMR (400 MHz, DMSO-*d*₆): δ 8.28-8.24 (*m*, 4H, ArH), 7.73-7.64 (*m*, 3H, ArH), 7.30 (*d*, *J* 7.9 Hz, 3H, ArH, NH₂), 6.79 (*br s*, 1H, NH₂), 4.84 (*d*, *J* 13.4 Hz, 2H, CH₂), 3.34 (*br s*, 2H, CH₂), 2.38 (*s*, 3H, Me), 1.96 (*d*, *J* 13.1 Hz, 2H, CH₂), 1.74-1.66 (*m*, 2H, CH₂). ¹³C-NMR (126 MHz, DMSO-*d*₆): δ 164.5, 162.6, 159.8, 139.8, 135.4, 132.8, 129.4, 129.0, 127.8, 28.4, 21.0. MS: 414.2 ([*M* + *H*]⁺, C₂₄H₂₄N₅O₂⁺, calc. 414.2). Anal. calc. for C₂₄H₂₃N₅O₂ (413.19): C 69.72, H 5.61, N 16.94, found: C 69.70, H 5.63, N 17.00.

1-(5-(4-Methylphenyl)-2-phenyl-oxazolo[4,5-d]pyrimidin-7-yl)piperidin-3-ol (6). Yield: 72%. mp 291 – 293 °C. ¹H-NMR (400 MHz, DMSO-*d*₆): δ 8.26 – 8.22 (*m*, 4H, ArH), 7.72 – 7.62 (*m*, 3H, ArH), 7.28 (*d*, *J* 8.0 Hz, 2H, ArH), 5.06 (*d*, *J* 4.2 Hz, 1H, OH), 4.47 (*br s*, 1H, CH), 4.28 (*br d*, *J* 13.2 Hz, 1H, CH), 3.71 (*br s*, 1H, CH), 3.64 – 3.58 (*m*, 1H, CH), 3.42 (*br s*, 1H, CH), 2.36 (*s*, 3H, Me), 1.97 – 1.86 (*m*, 2H, CH₂), 1.61 – 1.51 (*m*, 2H, CH₂). ¹³C-NMR (126 MHz, DMSO-*d*₆): δ 163.9, 161.5, 159.4, 147.8, 139.6, 135.2, 132.7, 129.4, 128.9, 127.7, 127.7, 125.7, 65.0, 32.7, 22.4, 21.0. MS: 387.0 ([*M* + *H*]⁺, C₂₃H₂₃N₄O₂⁺, calc. 387.2). Anal. calc. for C₂₃H₂₂N₄O₂ (386.17): C 71.48, H 5.74, N 14.50, found: C 71.46, H 5.70, N 14.56.

5-(4-Methylphenyl)-3-(2-phenyl-oxazolo[4,5-d]pyrimidin-7-yl)-1,2,3,4,5,6-hexahydro-8H-1,5-methanopyrido[1,2-*a*][1,5]diazocin-8-one (7). Yield: 78%. mp 263 – 265 °C. ¹H-NMR (400 MHz, DMSO-*d*₆): δ 8.30 – 8.23 (*m*, 2H, ArH), 8.20 – 8.17 (*m*, 2H, ArH), 7.75 – 7.62 (*m*, 3H, ArH), 7.28 (*d*, *J* 8.0 Hz, 2, ArH H), 7.04 (*br s*, 1H, HetH), 6.34 (*d*, *J* 6.9 Hz, 1H, HetH), 5.90 (*d*, *J* 9.0 Hz, 1H, HetH), 5.12 (*br s*, 1H, CH), 4.88 (*br s*, 1H, CH), 4.03 (*d*, *J* 15.6 Hz, 1H, CH), 3.70 – 3.40 (*m*, 4H, CH₂), 2.68 (*br s*, 1H, CH), 2.37 (*s*, 3H, Me), 2.18 (*br d*, *J* 12.9 Hz, 1H, CH), 2.07 (*br d*, *J* 12.7 Hz, 1H, CH). ¹³C-NMR (126 MHz, DMSO-*d*₆): δ 164.1, 161.8, 161.7, 159.2, 157.5, 147.9, 146.1, 139.7, 138.5, 135.0, 132.9, 129.4, 128.9, 127.7, 127.0, 125.5, 115.7, 104.8, 48.5, 34.3, 27.5, 25.6, 21.0. MS: 476.2 ([*M* + *H*]⁺, C₂₉H₂₆N₅O₂⁺, calc. 476.2). Anal. calc. for C₂₉H₂₅N₅O₂ (475.20): C 73.25, H 5.30, N 14.73, found: C 73.22, H 5.28, N 14.74.

5-(4-Methylphenyl)-2-phenyl-7-(4-(2-(pyridin-4-yl)ethyl)piperazin-1-yl)-oxazolo[4,5-d]pyrimidine (8). Yield: 86%. mp 188 – 190 °C. ¹H-NMR (400 MHz, DMSO-*d*₆): δ 8.47 – 8.46 (*m*, 2H, ArH), 8.27 – 8.24 (*m*, 4H, ArH), 7.72 – 7.63 (*m*, 3H, ArH), 7.32 – 7.28 (*m*, 4H, ArH), 4.04 (*br s*, 4H, CH₂), 2.83 (*t*, *J* 7.5 Hz, 2H, CH₂), 2.67 – 2.64 (*m*, 6H, CH₂), 2.37 (*s*, 3H, Me). ¹³C NMR (126 MHz, DMSO-*d*₆): δ 164.2, 161.7, 159.5, 152.4, 149.4, 147.7, 139.7, 135.1, 132.8, 129.4, 129.0, 127.7, 125.6, 124.3, 58.1, 52.3, 31.7, 21.0. MS: 477.2 ([*M* + *H*]⁺, C₂₉H₂₉N₆O⁺, calc. 477.2). Anal. calc. for C₂₉H₂₈N₆O (476.23): C 73.09, H 5.92, N 17.63, found: C 73.05, H 5.90, N 17.58.

5-(4-Methylphenyl)-2-phenyl-7-(4-(2-(pyridin-4-yl)ethyl)-1,4-diazepan-1-yl)-oxazolo[4,5-d]pyrimidine (9). Yield: 82%. mp 135 – 137 °C. ¹H-NMR (400 MHz, DMSO-*d*₆): δ 8.33 (*d*, *J* 4.8 Hz, 2H, HetH), 8.28 – 8.25 (*m*, 2H, ArH), 8.21 (*d*, *J* 7.3 Hz, 2H, ArH), 7.70 – 7.62 (*m*, 3H, ArH), 7.29 (*d*, *J* 7.7 Hz, 2H, ArH), 7.19 (*d*, *J* 5.0 Hz, 2H, HetH), 4.07 (*s*, 4H, CH₂), 2.98 (*s*, 2H, CH₂), 2.73 (*s*, 6H, CH₂), 2.37 (*s*, 3H, Me), 1.96 (*s*, 2H, CH₂). ¹³C-NMR (126 MHz, DMSO-*d*₆): δ 164.4, 161.2, 159.5, 149.5, 149.1, 148.0, 139.6, 135.3, 132.7, 129.4, 128.9, 127.7, 127.6, 125.8, 124.2, 57.2, 53.7, 32.4, 21.0. MS: 491.0 ([*M* + *H*]⁺, C₃₀H₃₁N₆O⁺, calc. 491.3). Anal. calc. for C₃₀H₃₀N₆O (490.25): C 73.45, H 6.16, N 17.13, found: C 73.42, H 6.15, N 17.20.

General procedure for the synthesis of oxazolo[4,5-*d*]pyrimidines 10-15. To a solution of one of 7-piperazinyl- or 7-(1,4-diazepanyl)substituted oxazolo[4,5-*d*]pyrimidines **V** (1 mmol) and triethylamine (1 mmol) in dioxane (10 mL) was added one of alkyl(aryl)sulfonyl chlorides (1 mmol). The reaction mixture was heated at 105 – 110 °C for 6 h. After removal of the solvent, the residue was triturated with water, filtered off, dried, and recrystallized.

7-(4-(Methylsulfonyl)piperazin-1-yl)-2-(4-methylphenyl)-5-phenyl-oxazolo[4,5-*d*]pyrimidine (10). Yield: 75%. mp 289 – 291 °C. ¹H-NMR (400 MHz, CDCl₃): δ 8.50 – 8.43 (*m*, 2H, ArH), 8.12 (*d*, *J* 8.2 Hz, 2H, ArH), 7.49 – 7.42 (*m*, 3H, ArH), 7.35 (*d*, *J* 7.8 Hz, 2H, ArH), 4.23 (*t*, *J* 5.1 Hz, 4H, CH₂ (piperazinyl)), 3.47 (*t*, *J* 5.0 Hz, 4H, CH₂ (piperazinyl)), 2.85 (*d*, *J* 1.6 Hz, 3H, Me), 2.46 (*s*, 3H, Me). ¹³C-NMR (126 MHz, CDCl₃): δ 165.7, 163.1, 156.9, 147.6, 137.9, 130.0, 128.5, 128.2, 45.8, 34.2, 21.3. MS: 450.0 ([*M* + H]⁺, C₂₃H₂₄N₅O₃S⁺, calc. 450.2). Anal. calc. for C₂₃H₂₃N₅O₃S (449.15): C 61.45, H 5.16, N 15.58, S 7.13, found: C 61.50, H 5.15, N 15.50, S 7.10.

2-(4-Methylphenyl)-5-phenyl-7-(4-(phenylsulfonyl)piperazin-1-yl)oxazolo[4,5-*d*]pyrimidine (11). Yield: 73%. mp 247 – 249 °C. ¹H-NMR (400 MHz, CDCl₃): δ 8.43 (*br d*, *J* 6.1 Hz, 2H, ArH), 8.11 (*d*, *J* 7.8 Hz, 2H, ArH), 7.80 (*d*, *J* 7.5 Hz, 2H, ArH), 7.60 – 7.52 (*m*, 3H, ArH), 7.44 (*br s*, 3H, ArH), 7.34 (*d*, *J* 7.7 Hz, 2H, ArH), 4.23 (*br s*, 4H, CH₂ (piperazinyl)), 3.25 (*br s*, 4H, CH₂ (piperazinyl)), 2.46 (*s*, 3H, Me). ¹³C-NMR (126 MHz, CDCl₃): δ 158.2, 143.9, 135.6, 133.4, 130.6, 130.0, 129.5, 128.6, 128.5, 128.3, 127.9, 46.1, 44.8, 22.0. MS: 512.0 ([*M* + H]⁺, C₂₈H₂₆N₅O₃S⁺, calc. 512.2). Anal. calc. for C₂₈H₂₅N₅O₃S (511.17): C 65.74, H 4.93, N 13.69, S 6.27, found: C 65.70, H 4.91, N 13.70, S 6.25.

2-(4-Methylphenyl)-5-phenyl-7-(4-tosylpiperazin-1-yl)oxazolo[4,5-*d*]pyrimidine (12). Yield: 72%. mp 261 – 263 °C. ¹H-NMR (400 MHz, CDCl₃): δ 8.46 – 8.39 (*m*, 2H, ArH), 8.09 (*d*, *J* 7.9 Hz, 2H, ArH), 7.66 (*d*, *J* 8.3 Hz, 2H, ArH), 7.46 – 7.40 (*m*, 3H, ArH), 7.32 (*t*, *J* 7.8 Hz, 4H, ArH), 4.20 (*t*, *J* 5.0 Hz, 4H, CH₂ (piperazinyl)), 3.21 (*t*, *J* 5.0 Hz, 4H, CH₂ (piperazinyl)), 2.45 (*s*, 3H, Me), 2.39 (*s*, 3H, Me). ¹³C-NMR (126 MHz, CDCl₃): δ 165.6, 163.2, 160.7, 147.4, 144.3, 143.7, 137.9, 132.4, 130.3, 130.0, 129.9, 128.4, 128.3, 128.2, 127.9, 127.8, 123.3, 46.1, 44.6, 21.9, 21.7. MS: 526.2 ([*M* + H]⁺, C₂₉H₂₈N₅O₃S⁺, calc. 526.2). Anal. calc. for C₂₉H₂₇N₅O₃S (525.18): C 66.27, H 5.18, N 13.32, S 6.10, found: C 66.25, H 5.15, N 13.24, S 6.20.

7-(4-(Methylsulfonyl)piperazin-1-yl)-2,5-diphenyl-oxazolo[4,5-*d*]pyrimidine (13). Yield: 71%. mp 275 – 277 °C. ¹H-NMR (400 MHz, CDCl₃): δ 8.51 – 8.44 (*m*, 2H, ArH), 8.29 – 8.22 (*m*, 2H, ArH), 7.66 – 7.52 (*m*, 3H, ArH), 7.50 – 7.43 (*m*, 3H, ArH), 4.26 (*t*, *J* 5.1 Hz, 4H, CH₂ (piperazinyl)), 3.48 (*t*, *J* 5.1 Hz, 4H, CH₂ (piperazinyl)), 2.85 (*s*, 3H, Me). ¹³C-NMR (151 MHz, CDCl₃): δ 164.3, 162.0, 160.1, 153.2, 143.6, 136.9, 132.0, 129.5, 128.3, 127.5, 127.2, 126.7, 125.1, 44.8, 33.9. MS: 436.0 ([*M* + H]⁺, C₂₂H₂₂N₅O₃S⁺, calc. 436.1). Anal. calc. for C₂₂H₂₁N₅O₃S (435.14): C 60.68, H 4.86, N 16.08, S 7.36, found: C 60.65, H 4.86, N 16.00, S 7.30.

2-(4-Methylphenyl)-5-phenyl-7-(4-(phenylsulfonyl)-1,4-diazepan-1-yl)oxazolo[4,5-*d*]pyrimidine (14). Yield: 74%. mp 229 – 231 °C. ¹H-NMR (400 MHz, DMSO-*d*₆): δ 8.34 – 8.31 (*m*, 2H, ArH), 8.04 (*d*, *J* 7.8 Hz, 2H, ArH), 7.68 (*d*, *J* 7.6 Hz, 2H, ArH), 7.49 – 7.36 (*m*, 8H, ArH), 4.09 (*t*, *J* 5.6 Hz, 2H, CH₂ (diazepanyl)), 3.98 (*t*, *J* 5.6 Hz, 2H, CH₂ (diazepanyl)), 3.61 (*t*, *J* 5.6 Hz, 2H, CH₂ (diazepanyl)), 3.41 (*br s*, 2H, CH₂ (diazepanyl)), 2.39 (*s*, 3H, Me), 1.98 (*br s*, 2H, CH₂ (diazepanyl)). ¹³C-NMR (126 MHz, DMSO-*d*₆): δ 164.4, 161.4, 159.2, 147.2, 143.1, 139.2, 137.9, 132.6, 130.0, 129.9, 129.1, 128.3, 127.7, 127.6, 127.4, 126.4, 122.9, 46.9, 21.3. MS: 526.2 ([*M* + H]⁺, C₂₉H₂₈N₅O₃S⁺, calc. 526.2). Anal. calc. for C₂₉H₂₇N₅O₃S (525.18): C 66.27, H 5.18, N 13.32, S 6.10, found: C 66.31, H 5.20, N 13.36, S 6.15.

2-(4-Methylphenyl)-5-phenyl-7-(4-tosyl-1,4-diazepan-1-yl)oxazolo[4,5-*d*]pyrimidine (15). Yield: 77%. mp 192 – 194 °C. ¹H NMR (400 MHz, CDCl₃): δ 8.44 (*d*, *J* 6.0 Hz, 2H, ArH), 8.10 (*d*, *J* 7.9 Hz, 2H, ArH), 7.55 (*d*, *J* 8.0 Hz, 2H, ArH), 7.46 – 7.44 (*m*, 3H, ArH), 7.36 (*d*, *J* 8.0 Hz, 2H, ArH), 7.04 (*d*, *J* 7.9 Hz, 2H, ArH), 4.18 (*t*, *J* 5.5 Hz, 2H, CH₂ (diazepanyl)), 4.10 (*t*, *J* 6.3 Hz, 2H, CH₂ (diazepanyl)), 3.62 (*t*, *J* 5.6 Hz, 2H, CH₂ (diazepanyl)), 3.43 (*t*, *J* 6.0 Hz, 2H, CH₂ (diazepanyl)), 2.47 (*s*, 3H, Me), 2.27 (*s*, 3H, Me), 2.16 (*t*, *J* 6.6 Hz, 2H, CH₂ (diazepanyl)). ¹³C-NMR

(126 MHz, CDCl₃): δ 160.7, 143.6, 138.1, 130.2, 130.0, 129.7, 128.4, 128.1, 126.8, 123.6, 47.5, 21.9, 21.5. MS: 540.2 ($[M + H]^+$, C₃₀H₃₀N₅O₃S⁺, calc. 540.2). Anal. calc. for C₃₀H₂₉N₅O₃S (539.20): C 66.77, H 5.42, N 12.98, S 5.94, found: C 66.75, H 5.40, N 13.05, S 5.90.

Biology

Antiviral and cytotoxicity assays. The antiviral activity screening of the compounds was performed at the University of Alabama at Birmingham. The antiviral properties of the synthesized compounds were studied against four DNA viruses belonging to the families *Herpesviridae* (HSV-1, HCMV, and VZV) and *Polyomaviridae* (BKV). Evaluation of activity was performed in 384 well plates by methods previously reported¹³⁻¹⁶ Briefly, drugs were diluted in 384 well plates with cells seeded prior to, or added after, the dilutions. Drug and control concentration ranged from 0.048 to 150 μ M, vehicle was DMSO. Virus was then added at the appropriate MOI (for antiviral assessment) or media (for cytotoxic assessment) and the plates incubated for 2 – 14 days (37 °C, 5% CO₂), according to the virus used. For endpoint determinations, the plates were harvested/treated as indicated (Table 3). Results for tested compound were reported as EC₅₀ and CC₅₀ that are of concentrations reducing viral replication and cell viability by 50% with respect to the untreated control. SI₅₀ value is a selectivity index calculated as a ratio of CC₅₀/EC₅₀.

Table 3. Viruses and assays used for determination of antiviral activity and cytotoxicity of synthesized compounds (cell line HFF)

Virus (Strain)	Control Assay Name
Herpes simplex virus 1 (E-377)	CellTiter-Glo (Cytopathic effect/Toxicity)
Human cytomegalovirus (AD169)	CellTiter-Glo (Cytopathic effect/Toxicity)
Varicella-Zoster virus (Ellen)	CellTiter-Glo (Cytopathic effect/Toxicity)
BK polyomavirus (Gardner)	Quantitative polymerase chain reaction (DNA)/CellTiter-Glo (Toxicity)

Acknowledgements

We would like to thank Enamine Ltd for the material and technical support. These studies were funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract Nos. HHSN272201100016I (MNP) and HHSN75N93019D00016 (SHJ). We thank the National Research Foundation of Ukraine ([2020.01/0075](#) NRFU competition "Science for the Security of Human and Society") for financial support.

Supplementary Material

Copies of the ¹H NMR, ¹³C NMR and LCMS spectra and ADMET properties of compounds **1-15** predicted by pkCSM online server (Table S1) are given in the Supplementary Material file associated with this manuscript.

References

1. De Coen, L.; Roman, B.; Movsisyan, M.; Heugebaert, T.; Stevens, C. *Eur. J. Org. Chem.* **2018**, 2018, 2148–2166.
<https://doi.org/10.1002/ejoc.201800133>
2. Zhirnov, V.V.; Velihina, Ye.S.; Mitiukhin, O.P.; Brovarets, V.S. *Chem. Biol. Drug Des.* **2021**, 98, 561–581.
<https://doi.org/10.1111/cbdd.13911>
3. Myllymäki, M.J.; Käsänen, H.; Kataja, A.O.; Lahtela-Kakkonen, M.; Saario, S.M.; Poso, A.; Koskinen, A.M. *Eur. J. Med. Chem.* **2009**, 44, 4179–4191.
<https://doi.org/10.1016/j.ejmech.2009.05.012>
4. Velihina, Ye.S.; Kachaeva, M.V.; Pilyo, S.G.; Zhirnov, V.V.; Brovarets, V.S. *Der Pharma Chem.* **2018**, 10, 1–10.
5. Velihina, Ye.S.; Kachaeva, M.V.; Pilyo, S.G.; Mitiukhin, O.P.; Zhirnov, V.V.; Brovarets, V.S. *Chem. R.J.* **2018**, 3, 81–93.
6. Velihina, Ye.; Scattolin, T.; Bondar, D.; Pil’o, S.; Obernikhina, N.; Kachkovskiy, O.; Semenyuta, I.; Caligiuri, I.; Rizzolio, F.; Brovarets, V.; Karpichev, Y.; Nolan, S.P. *Helv. Chim. Acta* **2020**, 103, e2000169.
<https://doi.org/10.1002/hlca.202000169>
7. Kumar, S.; Deep, A.; Narasimhan, B. *Curr. Bioact. Compd.* **2019**, 15, 289–303.
<https://doi.org/10.2174/1573407214666180124160405>
8. Sochacka-Ćwikła, A.; Regiec, A.; Zimecki, M.; Artym, J.; Zaczyńska, E.; Kocięba, M.; Kochanowska, I.; Bryndal, I.; Pyra, A.; Mączyński, M. *Molecules* **2020**, 25, 3558.
<https://doi.org/10.3390/molecules25153558>
9. Kachaeva, M.; Pilyo, S.; Kornienko, A.; Prokopenko, V.; Zhirnov, V.; Prichard, M.; Keith, K.; Yang, G.; Wang, H.; Banerjee, N.; Chow, L.; Broker, T.; Brovarets, V. *Ibnosina J. Med. Biomed. Sci.* **2017**, 9, 111–118.
10. Drach, B.S.; Miskevich, G.N. *Russ. J. Organ. Chem.* **1974**, 10, 2315 (Chem. Abstr., **1975**, 82, 72843).
11. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. *Adv. Drug Deliv. Rev.* **1997**, 23, 3–25.
[https://doi.org/10.1016/S0169-409X\(96\)00423-1](https://doi.org/10.1016/S0169-409X(96)00423-1)
12. Pires, D.E.V.; Blundell, T.L.; Ascher, D.B. *J. Med. Chem.* **2015**, 58, 4066–4072.
<https://doi.org/10.1021/acs.jmedchem.5b00104>
13. Sidwell, R.W.; Smee, D.F. *Antiviral Res.* **2000**, 48, 1–16.
[https://doi.org/10.1016/S0166-3542\(00\)00125-X](https://doi.org/10.1016/S0166-3542(00)00125-X)
14. Hartline, C.B.; Keith, K.A.; Eagar, J.; Harden, E.A.; Bowlin, T.L.; Prichard, M.N. *Antiviral Res.* **2018**, 159, 104–112.
<https://doi.org/10.1016/j.antiviral.2018.09.015>
15. Keith, K.A.; Hartline, C.B.; Bowlin, T.L.; Prichard, M.N. *Antiviral Res.* **2018**, 159, 122–129.
<https://doi.org/10.1016/j.antiviral.2018.09.016>
16. Beadle, J.R.; Valiaeva, N.; Yang, G.; Yu, J.H.; Broker, T.R.; Aldern, K.A.; Harden, E.A.; Keith, K.A.; Prichard, M.N.; Hartman, T.; Buckheit, R.W. Jr.; Chow, L.T.; Hostetler, K.Y. *J. Med. Chem.* **2016**, 59, 10470–10478.
<https://doi.org/10.1021/acs.jmedchem.6b00659>

This paper is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>)